Phase 3 Readout~month

Phase 3 Topline: A Double-Blinded, Placebo-controlled, Double Dummy, Multi-center Randomized, Phase 3 Study to Evalua

Name: Phase 3 Topline: A Double-Blinded, Placebo-controlled, Double Dummy, Multi-center Randomized, Phase 3 Study to Evalua
Start: 2027-05-22

May 22, 2027

Company: ORAMED PHARMACEUTICALS INC. (ORMP)
Indication: Type 2 Diabetes Mellitus

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start Free Full Calendar

Phase 3 Topline: A Double-Blinded, Placebo-controlled, Double Dummy, Multi-center Randomized, Phase 3 Study to Evalua — ORMP Phase 3 Readout | BioSniper